Related stories
Hanmi Pharmaceutical Licenses Fabry Disease Therapy to BioMarin for $237.5 Million
Hanmi Pharmaceutical licensed its Fabry disease therapy to BioMarin in a deal valued at USD 237.5 million.
M impact | EQUITY | Oct 29, 2026, 10:55 PM UTC
Brazilian real weakens as dollar rises
The dollar rose amid doubts about fiscal adjustment under Lula's fourth term.
M impact | FX | Oct 29, 2026, 10:42 PM UTC
Mexican Peso Slips Against Dollar After Fed Announcement
The Mexican peso weakened against the dollar one day after the Fed announcement; no magnitude is provided.
M impact | FX | Oct 29, 2026, 10:41 PM UTC
Euro edges up after ECB holds rates
The euro edged up after the European Central Bank kept interest rates unchanged.
M impact | FX | Oct 29, 2026, 09:42 PM UTC
Euro Rises Against Dollar After ECB Holds Rates Steady
The euro rose against the dollar after the European Central Bank kept rates unchanged.
M impact | FX | Oct 29, 2026, 09:25 PM UTC
Euro edges higher after ECB holds rates steady
The euro edged higher against the dollar after the European Central Bank kept rates unchanged.
M impact | FX | Oct 29, 2026, 09:14 PM UTC